

**Anti-TNFSF2 / TNFa Reference Antibody (infliximab)
Recombinant Antibody
Catalog # APR10177**

Specification

Anti-TNFSF2 / TNFa Reference Antibody (infliximab) - Product Information

Application	FC, E, FTA
Primary Accession	P01375
Reactivity	Cynomolgus, Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	145.98 KDa

Anti-TNFSF2 / TNFa Reference Antibody (infliximab) - Additional Information

Target/Specificity
TNFSF2 / TNFa

Endotoxin
< 0.001EU/ µg,determined by LAL method.

Conjugation
Unconjugated

Expression system
CHO Cell

Format
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

Storage
-80°C for 2 years under sterile conditions □ -20°C for 1 year under sterile conditions □ Avoid repeated freeze-thaw cycles.

Anti-TNFSF2 / TNFa Reference Antibody (infliximab) - Protein Information

Name TNF

Synonyms TNFA, TNFSF2

Function
Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs regulatory T- cells (Treg) function in individuals with rheumatoid arthritis via FOXP3 dephosphorylation. Up-regulates the expression of protein phosphatase 1 (PP1), which

dephosphorylates the key 'Ser-418' residue of FOXP3, thereby inactivating FOXP3 and rendering Treg cells functionally defective (PubMed: [23396208](http://www.uniprot.org/citations/23396208)). Key mediator of cell death in the anticancer action of BCG-stimulated neutrophils in combination with DIABLO/SMAC mimetic in the RT4v6 bladder cancer cell line (PubMed: [16829952](http://www.uniprot.org/citations/16829952)), PubMed: [22517918](http://www.uniprot.org/citations/22517918), PubMed: [23396208](http://www.uniprot.org/citations/23396208)). Induces insulin resistance in adipocytes via inhibition of insulin-induced IRS1 tyrosine phosphorylation and insulin-induced glucose uptake. Induces GKAP42 protein degradation in adipocytes which is partially responsible for TNF-induced insulin resistance (By similarity). Plays a role in angiogenesis by inducing VEGF production synergistically with IL1B and IL6 (PubMed: [12794819](http://www.uniprot.org/citations/12794819)). Promotes osteoclastogenesis and therefore mediates bone resorption (By similarity).

Cellular Location


Cell membrane; Single-pass type II membrane protein [Tumor necrosis factor, soluble form]; Secreted [C-domain 2]: Secreted.

Anti-TNFSF2 / TNF α Reference Antibody (infliximab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


Anti-TNFSF2 / TNF α Reference Antibody (infliximab) - Images



Anti-TNFSF2 / TNF α Reference Antibody (infliximab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-TNFSF2 / TNFa Reference Antibody (infliximab) is more than 100% ,determined by SEC-HPLC.



Immobilized human TNFa, Fc tag at 2 µg/mL can bind Anti-TNFSF2 / TNFa Reference Antibody (infliximab) □EC50=0.03538 µg/mL